Designed for Precision.
Developed for Life.
Adcendo ApS is a global clinical-stage biotech company dedicated to developing highly differentiated first and best-in-class antibody-drug conjugates (ADCs) for targeted treatment of cancer.
Latest News
Adcendo ApS Announces FDA Fast Track Designation Granted to ADCE-D01 for the Treatment of Soft Tissue Sarcoma
ADCE-D01 is a first-in-class antibody-drug conjugate targeting uPARAP, an endocytic receptor highly overexpressed in mesenchymal cancers including multiple soft tissue sarcoma subtypes Fast Track designation underscores the potential for ADCE-D01 to address the...
Adcendo ApS to Participate in Upcoming September Investor Conferences
COPENHAGEN, Denmark, Aug. 27, 2025 – Adcendo, a clinical-stage biotech company pioneering the development of first and best-in-class ADCs for cancers with a high unmet medical need, today announced that management will participate in five upcoming investor...
Adcendo ApS Announces First Patient Dosed in Phase I/II ADCElerate1 Trial of ADCE-D01
ADCE-D01 is a first-in-class antibody-drug conjugate (ADC) targeting uPARAP, an endocytic receptor highly overexpressed in mesenchymal cancers including multiple soft tissue sarcoma subtypes The ADCElerate1 trial will enroll patients in the US and Europe Copenhagen,...